AbbVie Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
AbbVie Inc. (ABBV) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $291.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-03
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $291.00M, a 64.64% decline year-over-year.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $744.00M, a 200.00% increase year-over-year.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $1.26B, a 19.63% decline year-over-year.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $2.68B, a 3168.29% increase year-over-year.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $5.02B, a 81.94% increase from fiscal 2024.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $2.76B, a 254.37% increase from fiscal 2023.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $778.00M, a 11.62% increase from fiscal 2022.
- AbbVie Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $697.00M, a 37.99% decline from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $291.00M 10-Q · filed 2026-08-03 | $1.03B 10-Q · filed 2026-08-03 | $2.30B derived: sum of 3 quarters · filed 2026-08-03 | $4.98B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $744.00M 10-Q · filed 2026-05-08 | $2.01B derived: sum of 2 quarters · filed 2026-05-08 | $4.69B derived: sum of 3 quarters · filed 2026-05-08 | $5.51B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $1.26B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.94B derived: sum of 2 quarters · filed 2026-02-20 | $4.77B derived: sum of 3 quarters · filed 2026-08-03 | $5.02B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $2.68B 10-Q · filed 2025-11-04 | $3.50B derived: sum of 2 quarters · filed 2026-08-03 | $3.75B 10-Q · filed 2025-11-04 | $5.33B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $823.00M 10-Q · filed 2026-08-03 | $1.07B 10-Q · filed 2026-08-03 | $2.65B derived: sum of 3 quarters · filed 2026-08-03 | $2.73B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | $248.00M 10-Q · filed 2026-05-08 | $1.82B derived: sum of 2 quarters · filed 2026-05-08 | $1.90B derived: sum of 3 quarters · filed 2026-05-08 | $2.84B derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $1.57B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.66B derived: sum of 2 quarters · filed 2026-02-20 | $2.59B derived: sum of 3 quarters · filed 2026-02-20 | $2.76B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $82.00M 10-Q · filed 2025-11-04 | $1.02B derived: sum of 2 quarters · filed 2025-11-04 | $1.18B 10-Q · filed 2025-11-04 | $1.47B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $937.00M 10-Q · filed 2025-08-04 | $1.10B 10-Q · filed 2025-08-04 | $1.38B derived: sum of 3 quarters · filed 2026-02-20 | $1.45B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $164.00M 10-Q · filed 2025-05-09 | $446.00M derived: sum of 2 quarters · filed 2026-02-20 | $512.00M derived: sum of 3 quarters · filed 2026-02-20 | $792.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $282.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $348.00M derived: sum of 2 quarters · filed 2026-02-20 | $628.00M derived: sum of 3 quarters · filed 2026-02-20 | $778.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $66.00M 10-Q · filed 2024-11-04 | $346.00M derived: sum of 2 quarters · filed 2024-11-04 | $496.00M 10-Q · filed 2024-11-04 | $739.00M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | $280.00M 10-Q · filed 2024-08-07 | $430.00M 10-Q · filed 2024-08-07 | $673.00M derived: sum of 3 quarters · filed 2025-02-14 | $713.00M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-03-31 | $150.00M 10-Q · filed 2024-05-03 | $393.00M derived: sum of 2 quarters · filed 2025-02-14 | $433.00M derived: sum of 3 quarters · filed 2025-02-14 | $702.00M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2022-12-31 | $243.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $283.00M derived: sum of 2 quarters · filed 2025-02-14 | $552.00M derived: sum of 3 quarters · filed 2025-02-14 | $697.00M 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $40.00M 10-Q · filed 2023-11-06 | $309.00M derived: sum of 2 quarters · filed 2023-11-06 | $454.00M 10-Q · filed 2023-11-06 | $859.00M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $269.00M 10-Q · filed 2023-08-07 | $414.00M 10-Q · filed 2023-08-07 | $819.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.22B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $145.00M 10-Q · filed 2023-05-05 | $550.00M derived: sum of 2 quarters · filed 2024-02-20 | $952.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.08B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $405.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $807.00M derived: sum of 2 quarters · filed 2024-02-20 | $939.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.12B 10-K · filed 2024-02-20 | $962.00M 10-K · filed 2022-02-18 | |||
| 2021-09-30 | $402.00M 10-Q · filed 2022-11-04 | $390.00M 10-Q · filed 2021-11-02 | $534.00M derived: sum of 2 quarters · filed 2022-11-04 | $719.00M 10-Q · filed 2022-11-04 | $557.00M 10-Q · filed 2021-11-02 | $1.20B derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2021-06-30 | $132.00M 10-Q · filed 2022-08-04 | $97.00M 10-Q · filed 2021-08-02 | $317.00M 10-Q · filed 2022-08-04 | $167.00M 10-Q · filed 2021-08-02 | $795.00M derived: sum of 3 quarters · filed 2023-02-17 | $840.00M derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2021-03-31 | $185.00M 10-Q · filed 2022-05-06 | $70.00M 10-Q · filed 2021-05-07 | $663.00M derived: sum of 2 quarters · filed 2023-02-17 | $708.00M derived: sum of 3 quarters · filed 2023-02-17 | $1.56B derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | $478.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $523.00M derived: sum of 2 quarters · filed 2023-02-17 | $1.38B derived: sum of 3 quarters · filed 2023-02-17 | $1.38B 10-K · filed 2023-02-17 | $1.20B 10-K · filed 2021-02-19 | |||
| 2020-09-30 | $45.00M 10-Q · filed 2021-11-02 | $898.00M derived: sum of 2 quarters · filed 2021-11-02 | $898.00M 10-Q · filed 2021-11-02 | $1.04B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | $853.00M 10-Q · filed 2021-08-02 | $853.00M 10-Q · filed 2021-08-02 | $992.00M derived: sum of 3 quarters · filed 2022-02-18 | $992.00M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $139.00M derived: sum of 2 quarters · filed 2022-02-18 | $139.00M derived: sum of 3 quarters · filed 2022-02-18 | $230.00M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $139.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $139.00M derived: sum of 2 quarters · filed 2022-02-18 | $230.00M derived: sum of 3 quarters · filed 2022-02-18 | $385.00M 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | $91.00M derived: sum of 2 quarters · filed 2020-11-04 | $246.00M 10-Q · filed 2020-11-04 | $546.00M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | $91.00M 10-Q · filed 2020-08-04 | $246.00M 10-Q · filed 2020-08-04 | $546.00M derived: sum of 3 quarters · filed 2021-02-19 | $601.00M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | $155.00M 10-Q · filed 2020-05-08 | $455.00M derived: sum of 2 quarters · filed 2021-02-19 | $510.00M derived: sum of 3 quarters · filed 2021-02-19 | $510.00M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $355.00M derived: sum of 2 quarters · filed 2021-02-19 | $355.00M derived: sum of 3 quarters · filed 2021-02-19 | $424.00M 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $55.00M 10-Q · filed 2019-11-06 | $55.00M derived: sum of 2 quarters · filed 2019-11-06 | $124.00M 10-Q · filed 2019-11-06 | $436.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-05 | $69.00M 10-Q · filed 2019-08-05 | $381.00M derived: sum of 3 quarters · filed 2020-02-21 | $381.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $69.00M 10-Q · filed 2019-05-03 | $381.00M derived: sum of 2 quarters · filed 2020-02-21 | $381.00M derived: sum of 3 quarters · filed 2020-02-21 | $396.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | $312.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $312.00M derived: sum of 2 quarters · filed 2020-02-21 | $327.00M derived: sum of 3 quarters · filed 2020-02-21 | $327.00M 10-K · filed 2020-02-21 | ||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $15.00M derived: sum of 2 quarters · filed 2018-11-07 | $15.00M 10-Q · filed 2018-11-07 | $55.00M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $15.00M 10-Q · filed 2018-08-07 | $15.00M 10-Q · filed 2018-08-07 | $55.00M derived: sum of 3 quarters · filed 2019-02-27 | $135.00M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-04 | $40.00M derived: sum of 2 quarters · filed 2019-02-27 | $120.00M derived: sum of 3 quarters · filed 2019-02-27 | $190.00M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $120.00M derived: sum of 2 quarters · filed 2019-02-27 | $190.00M derived: sum of 3 quarters · filed 2019-02-27 | $200.00M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $80.00M 10-Q · filed 2017-11-07 | $150.00M derived: sum of 2 quarters · filed 2017-11-07 | $160.00M 10-Q · filed 2017-11-07 | $160.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $70.00M 10-Q · filed 2017-08-07 | $80.00M 10-Q · filed 2017-08-07 | $80.00M derived: sum of 3 quarters · filed 2018-02-16 | $80.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $10.00M 10-Q · filed 2017-05-05 | $10.00M derived: sum of 2 quarters · filed 2018-02-16 | $10.00M derived: sum of 3 quarters · filed 2018-02-16 | $33.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $0.00 derived: sum of 2 quarters · filed 2018-02-16 | $23.00M derived: sum of 3 quarters · filed 2018-02-16 | $150.00M 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-07 | $23.00M derived: sum of 2 quarters · filed 2016-11-07 | $150.00M 10-Q · filed 2016-11-07 | $178.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $23.00M 10-Q · filed 2016-08-05 | $150.00M 10-Q · filed 2016-08-05 | $178.00M derived: sum of 3 quarters · filed 2017-02-17 | $486.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $127.00M 10-Q · filed 2016-05-06 | $155.00M derived: sum of 2 quarters · filed 2017-02-17 | $463.00M derived: sum of 3 quarters · filed 2017-02-17 | $479.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $336.00M derived: sum of 2 quarters · filed 2017-02-17 | $352.00M derived: sum of 3 quarters · filed 2017-02-17 | $352.00M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $308.00M 10-Q · filed 2015-11-06 | $324.00M derived: sum of 2 quarters · filed 2015-11-06 | $324.00M 10-Q · filed 2015-11-06 | |||||
| 2014-06-30 | $16.00M 10-Q · filed 2015-08-07 | $16.00M 10-Q · filed 2015-08-07 | ||||||
| 2013-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $268.00M derived: sum of 2 quarters · filed 2016-02-19 | $338.00M derived: sum of 3 quarters · filed 2016-02-19 | $338.00M 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | $220.00M 10-Q · filed 2014-11-07 | $290.00M derived: sum of 2 quarters · filed 2014-11-07 | $290.00M 10-Q · filed 2014-11-07 | $318.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-06-30 | $70.00M 10-Q · filed 2014-08-07 | $70.00M 10-Q · filed 2014-08-07 | $98.00M derived: sum of 3 quarters · filed 2015-02-20 | $98.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 | $28.00M derived: sum of 2 quarters · filed 2015-02-20 | $28.00M derived: sum of 3 quarters · filed 2015-02-20 | $138.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2012-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $28.00M derived: sum of 2 quarters · filed 2015-02-20 | $138.00M derived: sum of 3 quarters · filed 2015-02-20 | $288.00M 10-K · filed 2015-02-20 | ||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $110.00M derived: sum of 2 quarters · filed 2013-11-12 | $260.00M 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | $110.00M 10-Q · filed 2013-08-09 | $260.00M 10-Q · filed 2013-08-09 | ||||||
| 2012-03-31 | $150.00M 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $673.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |